Sequoia Vaccines, Inc.

Sequoia Vaccines is a clinical stage pharmaceutical company discovering and developing new vaccines preventing bacterial infections and medicines treating cancers and bacterial infections. Sequoia’s lead clinical candidate is a vaccine for the prevention of recurrent urinary tract infections. A placebo-controlled Phase 2 study evaluating Sequoia’s vaccine will begin enrolling women with a history of recurrent urinary tract infections in 2022. Sequoia’s vaccine has received fast track designation by the FDA. Sequoia Vaccines was formed in 2012 by Sequoia Sciences, Prolog Ventures and Holton Capital to develop its vaccine for the prevention of recurrent urinary tract infections.